V体育平台登录 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2012 Jun 28;119(26):6379-81.
doi: 10.1182/blood-2012-03-418673. Epub 2012 May 18.

"VSports在线直播" Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen  1 , Joycelynne M Palmer, Sandra H Thomas, Ni-Chun Tsai, Len Farol, Auayporn Nademanee, Stephen J Forman, Ajay K Gopal
Affiliations

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen et al. Blood. .

Abstract

Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known VSports手机版. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92. 3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27. 8% and chronic GVHD was 56. 3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcomes. N = 18 patients with median follow-up of 14.0 months. (A) Kaplan-Meier survival probabilities overall survival (solid line) and progression-free survival (PFS; dashed line). OS was measured from stem cell infusion to death from any cause. PFS was defined as time from stem cell infusion to recurrence, progression, or death from any cause, whichever occurred first. (B) Cumulative incidence of relapse/progression (RPR; dashed line) and nonrelapse mortality (NRM; solid line), calculated as competing risks. The cumulative incidence of relapse/progression (RP) was defined as time from stem cell infusion to recurrence or progression. Nonrelapse mortality (NRM) was measured from transplant to death from any cause other than disease relapse or progression.
See this image and copyright information in PMC

References (VSports注册入口)

    1. Horning SJ, Fanale M, de Vos S, et al. International Conference on Malignant Lymphoma; Lugano, Switzerland. 2008. pp. iv120–iv121.
    1. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study: a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310–317. - PMC - PubMed
    1. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82(2):677–681. - "VSports最新版本" PubMed
    1. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455–462. - PubMed
    1. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418–425. - PMC - PubMed

VSports手机版 - Publication types

VSports最新版本 - MeSH terms